Literature DB >> 2866964

The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

H E Sluiter, F T Huysmans, T A Thien, R A Koene.   

Abstract

The hypotensive effect of vasodilator monotherapy in hypertension is attenuated by a baroreceptor-mediated increase in the sympathetic release of noradrenaline. Nifedipine induces a rise in noradrenaline release, but it is not known to affect noradrenaline-induced vascular contraction of smooth muscle to a clinically significant degree. The haemodynamic and hormonal effects of a single sublingual dose of nifedipine 20 mg in 8 moderately hypertensive patients have been studied before and during postsynaptic alpha 1-blockade with prazosin. The antihypertensive effect of nifedipine was significantly increased by prazosin pretreatment (fall in mean arterial pressure 60 min after nifedipine: -16.7% with and -8.5% without prazosin), despite similar increases in plasma noradrenaline. Prazosin alone caused no change in supine blood pressure for 2 h after an oral dose of 2 mg. The findings are in keeping with the hypothesis that prazosin blocks a compensatory reaction to vasodilatation caused by nifedipine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866964     DOI: 10.1007/bf00544078

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Alpha adrenoceptor blockade with oral prazosin.

Authors:  A B Pitterman; D E Rollins; D D Shen; A Hurwitz; K M Hassanein
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

2.  Prazosin: the first-dose phenomenon.

Authors:  R M Graham; I R Thornell; J M Gain; C Bagnoli; H F Oates; G S Stokes
Journal:  Br Med J       Date:  1976-11-27

3.  Acute treatment of hypertension with nifedipine.

Authors:  F T Huysmans; T A Thien; H E Sluiter; R A Koene
Journal:  Neth J Med       Date:  1983       Impact factor: 1.422

4.  Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension.

Authors:  L D Jee; L H Opie
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-19

5.  Attenuation of sympathetic vasoconstriction by nifedipine: the role of vascular alpha 2-adrenoceptors.

Authors:  M Saeed; J Holtz; D Elsner; E Bassenge
Journal:  Eur J Pharmacol       Date:  1983-10-14       Impact factor: 4.432

6.  Prazosin depression of baroreflex function in hypertensive man.

Authors:  E H Sasso; D T O'Connor
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

8.  Dependence of aldosterone stimulation in adrenal glomerulosa cells on calcium uptake: effects of lanthanum nd verapamil.

Authors:  J L Fakunding; K J Catt
Journal:  Endocrinology       Date:  1980-11       Impact factor: 4.736

9.  The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man.

Authors:  D McAreavey; A M Cumming; V P Sood; B J Leckie; J J Morton; G D Murray; J I Robertson
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

10.  Role of Ca2+ in response of adrenal glomerulosa cells to angiotensin II, ACTH, K+, and ouabain.

Authors:  E L Schiffrin; M Lis; J Gutkowska; J Genest
Journal:  Am J Physiol       Date:  1981-07
View more
  7 in total

1.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Nifedipine interactions in hypertensive patients.

Authors:  A Salvetti; A Magagna; B Abdel-Haq; M Lenzi; R Giovannetti
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  The pharmacodynamics and pharmacokinetics of the combination of nifedipine and doxazosin.

Authors:  R Donnelly; H L Elliott; P A Meredith; C A Howie; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 5.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

6.  The mechanism of action of calcium antagonists on arrhythmias in early myocardial ischaemia: studies with nifedipine and DHM9.

Authors:  M J Curtis; M J Walker
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

7.  Nifedipine-prazosin interaction in patients with essential hypertension.

Authors:  I Kiss; C Farsang
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.